Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)
Chandra Shekhar, Rajesh Nasam, Siva Ramakrishna Paipuri, Prakash Kumar, Kiranmai Nayani, Srihari Pabbaraja, Prathama S. Mainkar, S. Chandrasekhar
Abstract
The emergence and rapid spread of coronavirus disease 2019 (COVID-19), a potentially fatal disease, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has swiftly led to public health crisis worldwide. Hence vaccines and antiviral therapeutics are an important part of the healthcare response to combat the ongoing threat by COVID-19. Here, we report an efficient synthesis of nirmatrelvir (PF-07321332), an orally active SARS-CoV-2 main protease inhibitor.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)DrugCoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyMedicine2019-20 coronavirus outbreakAntiviral drugPublic healthDiseaseIntensive care medicinePharmacologyInfectious disease (medical specialty)Internal medicineOutbreakNursingComputational Drug Discovery MethodsSynthesis and biological activityHepatitis C virus research